Skip to main content

Landry Robert E's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Apr 1, 2022

Accession no.
0001883850-22-000028
Filed
Apr 1, 2022
Trade date
Mar 31-Apr 1, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $219.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Landry Robert ECIK 0001585160Officer (EVP Finance CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 31, 2022Common StockMOption exerciseAcquired+1,500$399.66+$599,49030,244Direct
Mar 31, 2022Common StockFTax withholdingDisposed−1,184$700.99−$829,972.1629,060Direct
Apr 1, 2022Common StockSSaleDisposed−301$695.50−$209,345.528,759Direct
Apr 1, 2022Common StockSSaleDisposed−15$701.98−$10,529.728,744Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 31, 2022Common StockMOption exerciseDisposed−1,500$0.00$03,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)